par Minini, Andrea;Annoni, Filippo 
;Peluso, Lorenzo ;Gouvêa Bogossian, Elisa ;Creteur, Jacques ;Taccone, Fabio
Référence Brain sciences, 11, 2, page (1-10), 186
Publication Publié, 2021-02
;Peluso, Lorenzo ;Gouvêa Bogossian, Elisa ;Creteur, Jacques ;Taccone, Fabio Référence Brain sciences, 11, 2, page (1-10), 186
Publication Publié, 2021-02
Article révisé par les pairs
| Résumé : | There is a persistent debate on the optimal target temperature to use during cooling procedures in cardiac arrest survivors. A large randomized clinical trial (RCT) including more than 900 patients showed that targeted temperature management (TTM) at 33° C had similar mortality and unfavorable neurological outcome (UO) rates as TTM at 36° C in out-of-hospital cardiac arrest patients with any initial rhythm. Since then, several observational studies have been published on the effects of changes in target temperature (i.e., from 33 to 36° C) on patients’ outcome. We performed a systematic literature search from 1 January 2014 to 4 December 2020 and identified nine retrospective studies (very low levels of certainty; high risk of bias), including 3799 patients, that evaluated TTM at 33° C vs. TTM at 36° C on the occurrence of UO (n = seven studies) and mortality (n = nine studies). TTM at 33° C was associated with a lower risk of UO when studies assessing neurological outcome with the Cerebral Performance Categories were analyzed (OR 0.80 [95% CIs 0.65–0.99]; p = 0.04). No differences in mortality were observed within the two TTM strategies. These results suggest that an inappropriate translation of TTM protocols from large well-conducted randomized trials into clinical management may result in unexpected effects on patients’ outcome. As for all newly commercialized drugs, epidemiological studies and surveillance programs with an adequate follow-up on large databases are necessary to understand how RCTs are implemented into medical practice. |
